ACRS - Aclaris Therapeutics Inc.

-

$undefined

N/A

(N/A)

Aclaris Therapeutics Inc. NASDAQ:ACRS Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.

Location: 640 Lee Rd Ste 200, Pennsylvania, 19087-5636, US | Website: www.aclaristx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

48.72M

Cash

113.6M

Avg Qtr Burn

-5.019M

Short % of Float

9.12%

Insider Ownership

2.65%

Institutional Own.

82.41%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2b

Data readout

ATI-1777 (JAK 1/3 inhibitor) Details
Atopic dermatitis, Skin disease/disorder

Phase 2b

Update

Bosakitug (ATI-045) Details
Asthma, Chronic rhinosinusitis with nasal polyps

Phase 2

Data readout

ATI-2138 Details
Skin disease/disorder, Atopic dermatitis

Phase 2a

Data readout

Phase 2a

Update

ATI-2138 (ITK/JAK3 inhibitor) Details
Autoimmune disease, Ulcerative colitis

Phase 2a

Initiation

ATI-2231 (MK2 inhibitor) Details
Solid tumor/s, Cancer, Pancreatic cancer, Metastatic breast cancer

Phase 1a

Update

ATI-052 Details
no known indication

IND

Submission

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued